Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
To provide use of Anecortave Acetate Sterile Suspension of 15mg for a series of five patients
with rubeosis iridis. Rubeosis iridis refers to neovascularization of the iris. It is caused
by a number of conditions which include, but are not limited to severe diabetic retinopathy,
central retinal vein occlusion, chronic inflammation, and infection. Anecortave acetate is an
angiostatic, experimental drug that is being tested to prevent the growth of blood vessels
under the retina in patients with age-related macular degeneration (AMD). Therefore, it is
logical to apply the usage of Anecortave to patient's with rubeosis iridis in order to reduce
the neovascularization stimulus and cause the regression of the abnormal iris vessels.